Related Experiment Video
Updated: Dec 18, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of
Derek Reichel1, Bien Sagong1, James Teh1
1Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California 90048, United States.
Abstract:
Despite significant efforts to improve glioblastoma multiforme (GBM) treatment, GBM remains one of the most lethal cancers. Effective GBM treatments require sensitive intraoperative tumor visualization and effective postoperative chemotherapeutic delivery. Unfortunately, the diffusive and infiltrating nature of GBM limits the detection of GBM tumors, and current intraoperative visualization methods limit complete tumor resection. In addition, although chemotherapy is often used to eliminate any cancerous tissue remaining after surgery, most chemotherapeutic drugs do not effectively cross the brain-blood barrier (BBB) or enter GBM tumors. As a result, GBM has limited treatment options with high recurrence rates, and methods that improve its complete visualization during surgery and treatment are needed. Herein, we report a fluorescent nanoparticle platform for the near-infrared fluorescence (NIRF)-based tumor boundary visualization and image-guided drug delivery into GBM tumors. Our nanoplatform is based on ferumoxytol (FMX), an FDA-approved magnetic resonance imaging-sensitive superparamagnetic iron oxide nanoparticle, which is conjugated with hepthamethine cyanine (HMC), a NIRF ligand that specifically targets the organic anion transporter polypeptides that are overexpressed in GBM. We have shown that HMC-FMX nanoparticles cross the BBB and selectively accumulate in the tumor using orthotopic GBM mouse models, enabling NIRF-based visualization of infiltrating tumor tissue. In addition, HMC-FMX can encapsulate chemotherapeutic drugs, such as paclitaxel or cisplatin, and deliver these agents into GBM tumors, reducing tumor size and increasing survival. Taken together, these observations indicate that HMC-FMX is a promising nanoprobe for GBM surgical visualization and drug delivery.
Insights
A new nanoparticle platform improves glioblastoma (GBM) treatment by enabling near-infrared fluorescence (NIRF) visualization for surgical guidance and delivering chemotherapy drugs directly to tumors, enhancing survival rates.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Glioblastoma multiforme (GBM) is a highly lethal brain cancer with limited treatment options.
- Current methods for GBM visualization and chemotherapy delivery are insufficient due to tumor invasiveness and the blood-brain barrier (BBB).
Purpose of the Study:
- To develop a novel nanoparticle platform for enhanced intraoperative GBM visualization and targeted drug delivery.
- To evaluate the efficacy of this platform in crossing the BBB and accumulating in GBM tumors.
Main Methods:
- Conjugation of ferumoxytol (FMX) nanoparticles with hepthamethine cyanine (HMC) to create HMC-FMX.
- Utilizing orthotopic GBM mouse models to assess BBB penetration, tumor accumulation, and NIRF visualization.
- Encapsulating chemotherapeutic drugs (paclitaxel, cisplatin) within HMC-FMX for targeted delivery.
Main Results:
- HMC-FMX nanoparticles successfully crossed the BBB and selectively accumulated in GBM tumors in mouse models.
- NIRF imaging enabled visualization of infiltrating GBM tumor tissue.
- Drug-loaded HMC-FMX reduced tumor size and increased survival rates in treated mice.
Conclusions:
- The HMC-FMX nanoplatform shows significant promise for improving GBM surgical visualization.
- This platform offers a viable strategy for image-guided, targeted chemotherapy delivery in GBM treatment.
- Further development of HMC-FMX could lead to improved outcomes for GBM patients.

